Combination therapeutics in complex diseases

被引：69

作者：

He, Bing ^{[1
,2
]}

Lu, Cheng ^{[1
,2
,3
]}

Zheng, Guang ^{[1
,2
]}

He, Xiaojuan ^{[1
,2
,3
]}

Wang, Maolin ^{[1
,2
]}

Chen, Gao ^{[1
,2
]}

Zhang, Ge ^{[1
,2
]}

Lu, Aiping ^{[1
,2
,3
]}

机构：

[1] Hong Kong Baptist Univ, Inst Adv Translat Med Bone & Joint Dis, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China

[2] HKBU Shenzhen Res Inst & Continuing Educ, Inst Integrated Bioinformed & Translat Sci, Shenzhen, Peoples R China

[3] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China

来源：

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE | 2016年 / 20卷 / 12期

关键词：

combination therapeutics; complex diseases; molecular network; PACLITAXEL PLUS GEMCITABINE; ACTIVE RHEUMATOID-ARTHRITIS; RANDOMIZED CONTROLLED-TRIAL; BONE HOMEOSTASIS; DRUG DISCOVERY; PHASE-3; TRIAL; BREAST-CANCER; DOUBLE-BLIND; NETWORK PHARMACOLOGY; UNTREATED MELANOMA;

D O I：

10.1111/jcmm.12930

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The biological redundancies in molecular networks of complex diseases limit the efficacy of many single drug therapies. Combination therapeutics, as a common therapeutic method, involve pharmacological intervention using several drugs that interact with multiple targets in the molecular networks of diseases and may achieve better efficacy and/or less toxicity than monotherapy in practice. The development of combination therapeutics is complicated by several critical issues, including identifying multiple targets, targeting strategies and the drug combination. This review summarizes the current achievements in combination therapeutics, with a particular emphasis on the efforts to develop combination therapeutics for complex diseases.

引用

页码：2231 / 2240

页数：10

共 117 条

[41] Network pharmacology: the next paradigm in drug discovery [J].

Hopkins, Andrew L. .

NATURE CHEMICAL BIOLOGY, 2008, 4 (11) :682-690

[42] Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial [J].

Howman, Andrew ;

Chapman, Tracey L. ;

Langdon, Maria M. ;

Ferguson, Caroline ;

Adu, Dwomoa ;

Feehally, John ;

Gaskin, Gillian J. ;

Jayne, David R. W. ;

O'Donoghue, Donal ;

Boulton-Jones, Michael ;

Mathieson, Peter W. .

LANCET, 2013, 381 (9868) :744-751

[43] The rise and fall of supervised machine learning techniques [J].

Jensen, Lars Juhl ;

Bateman, Alex .

BIOINFORMATICS, 2011, 27 (24) :3331-3332

[44] Intra-axonal Translation of SMAD1/5/8 Mediates Retrograde Regulation of Trigeminal Ganglia Subtype Specification [J].

Ji, Sheng-Jian ;

Jaffrey, Samie R. .

NEURON, 2012, 74 (01) :95-107

[45] Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials [J].

Johnson, JI ;

Decker, S ;

Zaharevitz, D ;

Rubinstein, LV ;

Venditti, J ;

Schepartz, S ;

Kalyandrug, S ;

Christian, M ;

Arbuck, S ;

Hollingshead, M ;

Sausville, EA .

BRITISH JOURNAL OF CANCER, 2001, 84 (10) :1424-1431

[46] Relating protein pharmacology by ligand chemistry [J].

Keiser, Michael J. ;

Roth, Bryan L. ;

Armbruster, Blaine N. ;

Ernsberger, Paul ;

Irwin, John J. ;

Shoichet, Brian K. .

NATURE BIOTECHNOLOGY, 2007, 25 (02) :197-206

[47] Multicomponent therapeutics for networked systems [J].

Keith, CT ;

Borisy, AA ;

Stockwell, BR .

NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (01) :71-U10

[48] Predicting Drug-Target Interactions Using Drug-Drug Interactions [J].

Kim, Shinhyuk ;

Jin, Daeyong ;

Lee, Hyunju .

PLOS ONE, 2013, 8 (11)

[49]

Kim SY, 2008, INT J ONCOL, V32, P89

[50] Prediction of drug gene associations via ontological profile similarity with application to drug repositioning [J].

Kissa, Maria ;

Tsatsaronis, George ;

Schroeder, Michael .

METHODS, 2015, 74 :71-82

← 1 2 3 4 5 6 7 8 9 10 →